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Abstract
Purpose. To determine the seroprevalence of specific IgM indicative of respiratory tract infection (RTI) due to Chlamydia
trachomatis (CT) among symptomatic infants.
Methodology. A descriptive study was conducted on young infants up to 5months old at the Bacterial Sexually Transmitted
Infections Reference Laboratory, National Centre for Epidemiology, Budapest, covering the period 2008–2016. Serum
samples from infants suffering from RTIs were screened with a micro-immunofluorescence test (Focus, Cypress, USA) for
the presence of anti-Chlamydia trachomatis-specific IgM. A parallel Bordetella pertussis screening was performed by an
indirect immunofluorescence test (Euroimmun, Lübeck, Germany) that detected specific IgM.
Results.The CT-specific serum IgM was highly reactive in 50 (19.1%) of the 262 neonates with RTIs, while all proved negative
for Bordetella pertussis-specific IgM.
Conclusion. Vertically transmitted C. trachomatis must be regarded as a common pathogen among symptomatic neonates
with RTIs in Hungary. Routine screening and treatment of pregnant women could be one option to help prevent these
conditions. Focused laboratory testing based on raised clinical awareness should enable early diagnosis and appropriate
therapy for symptomatic infants.
INTRODUCTION
Respiratory tract infection (RTI) is one of the most common
neonatal diseases. Its prevalence and mortality are strongly
dependent on socioeconomic circumstances, and it particu-
larly affects developing countries [1]. Other intrinsic risk
factors, such as prematurity of infants, also predispose for
RTIs [2]. Worldwide, pneumonia was the leading cause of
death in 2015, with an estimated 12.8% death rate among
children between 1 and 59months of age [3].
Neonatal RTIs may be caused by a wide range of pathogens
and occur via different transmission routes. The infected
birth canal itself may play an important aetiological role, as
vertical transmission of frequently transmitted bacteria (e.g.
Lancefield group B streptococci and enteric bacilli) and
Chlamydia trachomatis (CT) can occur [2]. As one of the
major pathogens causing sexually transmitted infections
(STIs), CT is responsible for an estimated 146million infec-
tions per year worldwide, and particularly affects young
people aged 15–28 years [4, 5]. The likelihood of women
becoming pregnant is increased in this age group and those
that do become pregnant may become a maternal source of
a potential CT infection in newborns.
The transmission rate from mother to child varies between
50–70%, and the estimated prevalence rates of neonatal CT
range from 4 to 60 per 1000 live births in developed coun-
tries [6].
Inclusion conjunctivitis, referred to as ophthalmia neonato-
rum (ON), affects about 30–50% of infected newborns,
while a more severe clinical manifestation, an RTI, develops
in 10–20% [7, 8]. Symptomatic chlamydial RTI is an inva-
sive disease that elicits a systemic immune response pro-
ducing CT-specific IgM, which can be used as a
confirmatory test in infants with symptoms suggestive of
CT-induced RTI [9].
Due to the lack of routine antenatal CT screening in Hun-
gary we had no prevalence data from which we could
deduce the actual risk of neonatal infections. Our aim was
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to assess the potential role of this pathogen in neonatal
RTIs, and discuss the potential value of installing such a sys-
tematic antenatal screening system to detect and treat CT.
Azithromycin (1 g in a single dose) is the preferred treat-
ment for maternal CT infection [5].
METHODS
Study population
From January 2008 until December 2016 serum samples
were collected from 262 neonates with clinical RTIs. The
age of the enrolled subjects varied between 1 and 20weeks.
Age, sex and hospital admission were recorded. The blood
samples were collected by neonatologists after diagnosis of
RTIs based on clinical (tachypnoea/persistent cough) and/
or radiological signs (hyperinflation; diffuse pulmonary
infiltrates). Forty-one per cent of the serum samples origi-
nated from medical institutes in the Hungarian capital,
Budapest, while 59% were referred from the countryside.
Laboratory methods
Serum samples from infants with RTIs were stored at
 20

C until further processing. A micro-immunofluores-
cence MIF test (Focus, Cypress, USA; catalogue number:
IF1250M) was used according to the manufacturer’s
instructions to detect CT-specific IgM in these serum sam-
ples. The assay was performed from 10 µl serum diluted
with 150 µl pretreatment diluent, and PBS was used to
determine the endpoint titres. Purified elementary bodies of
eight serotypes (D-K) of CT served as chlamydial antigens.
In positive cases the fluorescein-labelled antihuman IgM is
able to react with the antigen–human IgM complexes. Reac-
tive samples show bright green fluorescence. The cut-off
was defined at a serum dilution rate of 1 : 32, as this value is
considered to be diagnostic for infection [10]. As a result,
seronegative, weak seropositive (reactivity with dilution titre
<32) and strong seropositive (dilution titre 32) results
were obtained (Table 1).
Screening for Bordetella pertussis-specific IgM was per-
formed using an indirect immunofluorescence test (IIFT)
(Euroimmun, Lübeck, Germany; catalogue number: FI2050-
1005M) with whole bacterial antigen. Serum samples were
diluted to 1 : 100 as recommended in the manufacturer’s
instructions. Known cross-reactivity may be observed with
other Bordetella spp., but there is no report about CT cross-
reactivity. Further verification procedures, such as anti-per-
tussis toxin IgG determination, were not applied, as all these
samples proved IgM-negative, i.e. did not show any
fluorescence.
RESULTS
The male-to-female ratio of infants with RTIs was 149 male
versus 113 female infants (1.3). Two hundred and thirteen
out of 262 affected infants (81.3%) were hospitalized (126
male and 87 female; ratio, 1.4). Seronegative infants repre-
sented 65.3% (171/262) of the group, weak reactivity was
detected in 15.6% (41/262) of the group and 19.1% (50/
262) of the patients were found to be unequivocally
seropositive.
The age of the IgM-positive patients ranged between 3–
20weeks, with the median age being 9weeks. The gender
distribution showed an even stronger male dominance: 32
males versus 18 females (ratio, 1.8). Eighty per cent of sero-
positive babies needed hospital care (40/50), again with a
male dominance (25 males versus 15 females; ratio, 1.7).
The age and sex distribution, together with the inpatient/
outpatient rates, are outlined in Table 1.
Table 1. Age, gender-distribution and hospitalization rates for C. trachomatis IgM seropositive (SP) and weak reactive (WR)/nonreactive (NR)
neonates (N=262)
Postpartum age (weeks) Serostatus No. of hospitalized patients (N=213) No. of outpatient (N=49) All
Male Female Male Female
0–2 SP 0 0 0 0 16
WR/NR 9 7 0 0
3–4 SP 6 3 0 1 31
WR/NR 7 9 2 3
5–6 SP 5 4 1 0 38
WR/NR 17 6 3 2
7–10 SP 5 4 3 0 79
WR/NR 30 25 4 8
11–14 SP 5 1 1 2 60
WR/NR 23 18 4 6
15–20 SP 4 3 2 0 38
WR/NR 15 7 3 4
All SP 25 15 7 3 50 (19%)
WR/NR 101 72 16 23 212 (81%)
126 (48%) 87 (33%) 23 (9%) 26 (10%) 262
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From a differential diagnostic aspect, B. pertussis IgM seros-
tatus was also investigated, but none of the serum samples
was reported as positive in the laboratory database tested by
anti-Bordetella pertussis IgM IIFT.
DISCUSSION
The ‘classical’ type of chlamydial infantile pneumonia is
usually a late-onset disease, typically developing at 4–
12weeks of age, accompanied by a so-called ‘staccato’
cough. Rhinorrhoea may be a characteristic prodromal sign,
but fever is infrequent [11, 12]. ON is present in about half
of the cases, and is a valuable diagnostic clue, together with
peripheral eosinophilia [13, 14]. As the majority of clinical
symptoms and radiology signs are nonspecific, differential
diagnosis should be extended to the most prevalent viruses
(respiratory syncytial virus, adenovirus, cytomegalovirus,
etc.) and bacteria (Streptococcus pneumoniae, Staphylococ-
cus aureus, etc.), which can also predispose individuals to
late-onset respiratory infections [1, 15, 16]. One should note
that mixed infections with these respiratory pathogens may
also occur, and viral co-infection has been reported in a
higher proportion of severe cases compared to cases of mild
pneumonia. [11, 17].
As clinical signs often resemble pertussis (whooping cough),
this must also be considered, especially in unvaccinated
young infants. Its real risk depends on the actual epidemio-
logical situation, principally when similar cases are accumu-
lating and/or no vaccination can be assumed among the
contacts. In our series, we did not find any confirmed per-
tussis among study patients.
The gold standard for laboratory diagnosis of CT-RTI is
PCR examination of the nasopharyngeal aspirates for the
presence of CT, but only if these are collected before the
start of antibiotic therapy, to prevent false-negative PCR
results [5]. In this study most of the infants had already
received some antibiotic treatment, rendering the negative
results from PCR testing unreliable. For this reason, these
types of clinical samples were not collected from the major-
ity of our patients. In a prospective study focusing on differ-
ent chlamydial clinical manifestations in infants with
asymptomatic colonization versus symptomatic respiratory
infection, the incidence per 1000 live birth was found to be
6.5 and 2.1, respectively [18].
In the absence of relevant respiratory samples, the specific
IgM response can be detected by serological assays as a sup-
portive test [14, 19, 20]. As the maternal IgM do not pass
across the placenta, the presence of CT-specific IgM anti-
body in a newborn’s blood sample is indicative of a systemic
immune response from the neonate elicited by this invasive
type of infection.
The seronegative or weak seropositive C. trachomatis IgM
MIF titre results of <32 were not further investigated for
any pathogens, so the aetiology of these cases remained
unknown. In cases of weak seropositivity in clinically suspi-
cious patients, we advise retesting 2–4weeks later so as to
observe any changes in IgM titres. We think that weak posi-
tive samples may refer to an early sampling and an early
stage of immune response, rather than to a later stage of
recovery.
Male infants appear to be more vulnerable to RTIs than
females (ratio, 1.3), and also to severe infection requiring
hospitalization (ratio, 1.4), especially in respect of CT infec-
tion (ratio, 1.7), suggesting that males are more vulnerable
to severe CT RTI. This is very different in infants with ON,
where the male-to-female ratio was 0.9 for all ON, 1.0 for
CT-ON and 0.6 for severe ON requiring hospitalization
[21]. Further, the time of onset for CT-related disease dif-
fered: the median age of patients suffering from early-onset
CT ON was 2weeks, while it was 9 weeks in CT RTI cases.
These figures are similar to those in previously reported
data [13]. Only 6% of the RTI patients belonged to a youn-
ger age group than 4–12weeks, which also corresponds to
the clinical observations [11]. Compared to CT ON, the rate
of hospitalization from CT RTI was high at 80% (versus
6.7% for CT ON). This is due to the need for a more
detailed diagnosis, and for more prolonged therapy and fol-
low-up. Furthermore, in premature babies, the increased
risk of developing respiratory distress syndrome (RDS) may
also favour hospital admission [2].
Based on the positive IgM MIF results (titre 32), 50 of 262
infants were diagnosed with CT infection, which means a
seroprevalence of 19.1% in this group. Similarly, among
non-RSV infantile pneumonia cases, a CT prevalence of as
high as 17.1% was reported in the study of Khan and Potter
[22]. These prevalence data are far higher than the recently
published figure of 7% that was based on the direct PCR
detection of CT DNA [15]. This discrepancy may be attrib-
uted to the different detection methods, as specific IgM may
persist up to 3months in serum samples, while chlamydial
DNA rapidly disappears after antibiotic treatment [9].
As the background for diagnosis, PCR detects the patho-
gen’s DNA, while serology detects the specific IgM due to
an active immune response. The onset and quality of the
tests results are influenced by several extrinsic/intrinsic fac-
tors, for example antibiotic therapy, steroid treatment,
transfusion, plasmaferesis, infective dose of CT, the timing
of sample collection, etc., but in untreated cases with an
intact immune system one can expect a positive PCR result
first, which is then followed by massive IgM production.
The question of whether the titre of the IgM is influenced
by the infective dose, i.e. the copy number of the CT DNA,
needs further research.
The clinical significance of CT is supported by the observa-
tion that it is still being detected as the second most frequent
respiratory pathogen (after RSV) for infants less than
6months old in the Netherlands [15]. Detailed surveillance
reports are still lacking, but CT infection and testing should
always be considered when viral aetiology is excluded or less
likely [23].
Balla et al., Journal of Medical Microbiology
3
Limitations
Optimal laboratory diagnosis of chlamydial neonatal infec-
tions relies on the detection of CT DNA from nasopharyn-
geal aspirates. However, due to previous antibiotic therapy,
relevant samples of nasopharynx or conjunctivae were not
available from all patients suffering from RTIs, which made
the diagnosis of CT infection somewhat less definitive.
The maternal cervical samples were not available for parallel
CT testing, however this investigation would have provided
valuable additional data about CT prevalence in women, as
well as a possible explanation of the potential source of
infection in the seronegative or weak seroreactive infants.
Furthermore, it would have been informative to know the
distribution of the maternal chlamydial genotypes, as in a
previous study we confirmed that certain genotypes are
more likely to cause CT ON than others [21].
Conclusion
Neonatal STIs are still frequently undetected, misdiagnosed
or treated inappropriately. Focused screening and therapeu-
tic efforts are required to reduce the number of CT-infected
infants, while routine screening of pregnant women should
be implemented in order to potentially decrease the rate of
vertical transmission.
Our data demonstrate that C. trachomatis is still a leading
pathogen among respiratory neonatal infections in
Hungary. Chlamydial etiology was found in one-fifth of the
newborns with RTIs, in the first report of this kind in
Hungary to date. As the neonatal clinical manifestations are
the results of vertical transmission, this indicates CT infec-
tion of the mother and her sexual partner(s).
Summarizing our results, we would like to point out that
serology may be a useful and reliable alternative diagnostic
test when no respiratory samples are taken prior to antibi-
otic treatment for NAAT. Parallel testing of clinical samples
for most frequent respiratory pathogens enable targeted
therapy and recognition of a potentially mixed infection.
In addition to employing prenatal screening as a potential
tool of prevention, neonatalogists and neonatal nurses
should also be aware of the risks and prevalence of CT
infection, and know about correct sampling and laboratory
diagnosis. They have a crucial role in the early recognition
of ocular and respiratory chlamydial infections.
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